Results 151 to 160 of about 4,725,794 (315)

Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts

open access: yes, 2014
Michelle Cheng,1,* Samantha Ho,1,* Jun Hwan Yoo,1,2,* Deanna Hoang-Yen Tran,1,* Kyriaki Bakirtzi,1 Bowei Su,1 Diana Hoang-Ngoc Tran,1 Yuzu Kubota,1 Ryan Ichikawa,1 Hon Wai Koon1 1Center for Inflammatory Bowel Diseases, Division of Digestive Diseases ...
Su B   +9 more
core  

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

open access: yesAdvanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li   +11 more
wiley   +1 more source

Macrophage Trogocytosis of Tumor Cells Drives the Immunosuppression of Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
Trogocytosis efficiency varies significantly among different tumor cells and is inversely related to their cortical stiffness; this efficiency dictates the extent of immunosuppression via upregulation of CXCL5 and Arg‐1, ultimately driving CD8+T cell exhaustion and tumor escape.
Chao Liang   +9 more
wiley   +1 more source

The effect of the antioxidant, Coenzyme Q, on Coco-2 colon cells treated with iron to reduce lipid peroxidation [PDF]

open access: yes, 2002
Plan BThe objective of this study was to determine if Coenzyme Q10 (also known as ubiquinone) acting as an antioxidant, would protect against free radical damage to cell membranes that can cause cancer.
Johanknecht, Viva M.
core  

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

open access: yesAdvanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu   +14 more
wiley   +1 more source

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

open access: yesAdvanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li   +13 more
wiley   +1 more source

Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy

open access: yesAdvanced Science, EarlyView.
This work develops a metabolic sharing strategy that employs cytidine monophosphate (CMP) to competitively reprogram floxuridine (FUDR) pyrimidine metabolism in colorectal tumor cells. Elevated intracellular FdUMP induces nucleotide imbalance, drives mitochondrial DNA release and cGAS‐STING innate immune cascade activation, and potentiates robust ...
Chao Wang   +10 more
wiley   +1 more source

Mutant KRAS‐m6A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target

open access: yesAdvanced Science, EarlyView.
Mutant KRAS‐m6A axis promotes colorectal cancer (CRC) progression. Mutant KRAS stabilizes METTL3, leading to increased m6A‐modified BCL9L mRNA and translation of BCL9L protein. BCL9L in turn mediates TGF‐β secretion to induce differentiation of Treg and an immunosuppressive microenvironment.
Danyu Chen   +12 more
wiley   +1 more source

Colon Cancer [PDF]

open access: yesClinics in Colon and Rectal Surgery, 2015
openaire   +2 more sources

Home - About - Disclaimer - Privacy